The Current Evidence for the Use of Safinamide for the Treatment of Parkinson’s Disease

References

• KaliaLV, LangAE. Parkinson’s disease. Lancet. 2015;386(9996):896–912. doi:10.1016/S0140-6736(14)61393-325904081
   PubMed Web of Science ®Google Scholar
• FoxS. Non-dopaminergic treatments for motor control in parkinson’s disease. Drugs. 2013;73(13):1405–1415. doi:10.1007/s40265-013-0105-423917951
   PubMed Web of Science ®Google Scholar
• JennerP, CacciaC. The role of glutamate in the healthy brain and in the pathophysiology of parkinson’s disease. Eur Neurol Rev. 2019;14(Suppl. 2):2–12.
   Google Scholar
• CalabresiP, KulisevskyJ. Safinamide as add-on therapy – moving beyond dopamine for a multifaceted approach in parkinson’s disease. Eur Neurol Rev. 2017;12(Suppl. 5):2–6.
   Google Scholar
• PolitisM, NiccoliniF. Serotonin in parkinson’s disease. Behav Brain Res. 2015;277:136–145. doi:10.1016/j.bbr.2014.07.03725086269
   PubMed Web of Science ®Google Scholar
• O’CallaghanC, LewisSJG. Cognition in parkinson’s disease. Int Rev Neurobiol. 2017;133:557–583. doi:10.1016/bs.irn.2017.05.00228802933
   PubMed Web of Science ®Google Scholar
• OlanowCW, StocchiF. Safinamide – a new therapeutic option to address motor symptoms and motor complications in mid-to-late-stage parkinson’s disease. Eur Neurol Rev. 2016;11(Suppl. 2):2–15.
   Google Scholar
• FabbriM, RosaMM, FerreiraJJ. Adjunctive therapies in parkinson’s disease: how to choose the best treatment strategy approach. Drugs Aging. 2018;35(12):1041–1054. doi:10.1007/s40266-018-0599-230318555
   PubMed Web of Science ®Google Scholar
• OparaJA, BrolaW, LeonardiM, et al. Quality of life in Parkinson’s disease. J Med Life. 2012;5(4):375–381.23346238
   PubMedGoogle Scholar
• BlairHA, DhillonS. Safinamide: a review in parkinson’s disease. CNS Drugs. 2017;31(2):169–176. doi:10.1007/s40263-017-0408-128110399
   PubMed Web of Science ®Google Scholar
• WasanH, SinghD, ReetaKH. Safinamide in neurological disorders and beyond: evidence from preclinical and clinical studies. Brain Res Bull. 2021;168:165–177. doi:10.1016/j.brainresbull.2020.12.01833387637
   PubMed Web of Science ®Google Scholar
• AlborghettiM, NicolettiF. Different generations of type-B monoamine oxidase inhibitors in parkinson’s disease: from bench to bedside. Curr Neuropharmacol. 2018;16:1–13. doi:10.2174/1570159X160117121409310029403342
   PubMed Web of Science ®Google Scholar
• KulisevskyJ. Emerging role of safinamide in parkinson’s disease therapy. Eur Neurol Rev. 2014;9(2):108–112. doi:10.17925/ENR.2014.09.02.108
   Google Scholar
• ReichmannH, BaroneP, PoeweW. Progression of parkinson’s disease and unmet needs in mid- to late-stage patients. Eur Neurol Rev. 2015;10:182–188. doi:10.17925/ENR.2015.10.02.182
   Google Scholar
• GuerraA, SuppaA, D’OnofrioV, et al. Abnormal cortical facilitation and L-dopa-induced dyskinesia in parkinson’s disease. Brain Stimul. 2019;12(6):1517–1525. doi:10.1016/j.brs.2019.06.01231217080
   PubMed Web of Science ®Google Scholar
• Xadago® - summary of product characteristics, approved by EMA on 24/02/15. Summary of product characteristics. Available from: https://www.medicines.org.uk/emc/product/2159/smpc. Accessed 531, 2021.
   Google Scholar
• BorgohainR, SzaszJ, StanzioneP, et al. Randomized trial of safinamide add-on to levodopa in parkinson’s disease with motor fluctuations. Mov Disord. 2014;29(2):229–237. doi:10.1002/mds.2575124323641
   PubMed Web of Science ®Google Scholar
• BorgohainR, SzaszJ, StanzioneP, et al. Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late parkinson’s disease. Mov Disord. 2014;29(10):1273–1280. doi:10.1002/mds.2596125044402
   PubMed Web of Science ®Google Scholar
• SchapiraAHV, FoxS, HauserRA, et al. Assessment of safety and efficacy of safinamide as a levodopa adjunct in patients with parkinson disease and motor fluctuations. JAMA Neurol. 2017;74(2):216–224. doi:10.1001/jamaneurol.2016.446727942720
   PubMed Web of Science ®Google Scholar
• HattoriN, TsuboiY, YamamotoA, SasagawaY, NomotoM. Efficacy and safety of safinamide as an add-on therapy to L-DOPA for patients with parkinson’s disease: a randomized, double-blind, placebo-controlled, phase II/III study. Park Rel Dis. 2020;75:17–23. doi:10.1016/j.parkreldis.2020.04.012
   Web of Science ®Google Scholar
• FoxSH, KatzenschlagerR, LimS-Y, et al. International parkinson and movement disorder society evidence-based medicine review: update on treatments for the motor symptoms of parkinson’s disease. Mov Dis. 2018;33(8):1248–1266. doi:10.1002/mds.27372
   PubMed Web of Science ®Google Scholar
• StocchiF, BorgohainR, OnofrjM, et al. A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early parkinson’s disease patients. Mov Dis. 2012;27:106–112. doi:10.1002/mds.23954
   PubMed Web of Science ®Google Scholar
• DézsiL, VécseiL. Safinamide for the treatment of parkinson’s disease. Expert Opin Investig Drugs. 2014;23:729–742. doi:10.1517/13543784.2014.897694
   PubMed Web of Science ®Google Scholar
• MullerT. Safinamide in the treatment of parkinson’s disease. Neurodegener Dis Manag. 2020;10:195–204. doi:10.2217/nmt-2020-001732648512
   PubMed Web of Science ®Google Scholar
• CattaneoC, SardinaM, BonizzoniE. Safinamide as add on therapy to levodopa in mid- to late-stage parkinson’s disease fluctuating patients. Post hoc analyses of studies 016 and SETTLE. Parkinsons Dis. 2016;6(1):165–173. doi:10.3233/JPD-150700
   Web of Science ®Google Scholar
• CattaneoC, JostWH, BonizzoniE. Long-term efficacy of safinamide on symptoms severity and quality of life in fluctuating parkinson’s disease patients. J Park Dis. 2020;10:89–97.
   Web of Science ®Google Scholar
• CattaneoC, La FerlaR, BonizzoniE, et al. Long-term effects of safinamide on dyskinesia in mid- to late-stage parkinson’s disease: a post-hoc analysis. J Parkinsons Dis. 2015;5(3):475–481. doi:10.3233/JPD-15056926406127
   PubMedGoogle Scholar
• CattaneoC, BaroneP, BonizzoniE, et al. Effects of safinamide on pain in fluctuating parkinson’s disease patients: a post-hoc analysis. J Parkinsons Dis. 2017;7(1):95–101. doi:10.3233/JPD-16091127802242
   PubMedGoogle Scholar
• CattaneoC, MullerT, BonizzoniE, LazzeriG, KottakisI, KeywoodC. Long-term effects of safinamide on mood fluctuations in parkinson’s disease. J Parkinsons Dis. 2017;7(4):629–634. doi:10.3233/JPD-17114328777756
   PubMedGoogle Scholar
• CattaneoC, KulisevskyJ, TubazioV, et al. Long-term efficacy of safinamide on parkinson’s disease chronic pain. Adv Ther. 2018;35(4):515–522. doi:10.1007/s12325-018-0687-z29542008
   PubMed Web of Science ®Google Scholar
• QureshiAR, RanaAQ, MalikSH, et al. Comprehensive examination of therapies for pain in parkinson’s disease: a systematic review and meta-analysis. Neuroepidemiology. 2018;51(3–4):190–206. doi:10.1159/00049222130153669
   PubMed Web of Science ®Google Scholar
• ManciniF, Di FonzoA, LazzeriG, et al. Real life evaluation of safinamide effectiveness in parkinson’s disease. Neurol Sci. 2018;39(4):733–739. doi:10.1007/s10072-018-3272-y29441484
   PubMed Web of Science ®Google Scholar
• PagonabarragaJ, KulisevskyJ. Safinamide from daily clinical practice: first clinical steps. Rev Neurol. 2017;65(10):433–438.29130466
   PubMed Web of Science ®Google Scholar
• Martí-AndrésG, Jiménez-BolañosR, Arbelo-GonzálezJM, et al. Safinamide in clinical practice: a Spanish Multicenter Cohort Study. Brain Sci. 2019;9:272. doi:10.3390/brainsci9100272
   Web of Science ®Google Scholar
• TsuboiY, HattoriN, YamamotoA, SasagawaY, NomotoM. Long-term safety and efficacy of safinamide as add-on therapy in levodopa-treated Japanese patients with parkinson’s disease with wearing-off: results of an open-label study. J Neurol Sci. 2020;416:117012. doi:10.1016/j.jns.2020.11701232673884
   PubMed Web of Science ®Google Scholar
• GeroinC, Di VicoIA, SquintaniGM, SegattiA, BoviT, TinazziM. Effects of safinamide on pain in parkinson’s disease with motor fluctuations: an exploratory study. J Neural Transm. 2020;127(8):1143–1152. doi:10.1007/s00702-020-02218-732572581
   PubMed Web of Science ®Google Scholar
• LiguoriC, StefaniA, RuffiniR, et al. Safinamide effect on sleep disturbances and daytime sleepiness in motor fluctuating Parkinson’s disease patients: a validated questionnaires-controlled study. Parkinsonism Relat Disord. 2018;57:80–81. doi:10.1016/j.parkreldis.2018.06.03330006034
   PubMed Web of Science ®Google Scholar
• BianchiMLE, RiboldazziG, MauriM, VersinoM. Efficacy of safinamide on non-motor symptoms in a cohort of patients affected by idiopatic parkinson’s disease. Neurol Sci. 2019;40:275–279. doi:10.1007/s10072-018-3628-330382437
   PubMed Web of Science ®Google Scholar
• RinaldiD, SforzaM, AssognaF, et al. Safinamide improves executive functions in fluctuating parkinson’s disease patients: an exploratory study. J Neural Transm. 2020. doi:10.1007/s00702-020-02259-y
   Web of Science ®Google Scholar
• RinaldiD, AssognaF, SforzaM, et al. Rasagiline for dysexecutive symptoms during wearing-off in parkinson’s disease: a pilot study. Neurol Sci. 2018;39(1):141–143. doi:10.1007/s10072-017-3123-2
   Web of Science ®Google Scholar
• EPAR Xadago. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=/pages/medicines/human/medicines/002396/human_med_001847.jsp. Accessed 531, 2021.
   Google Scholar
• Jumex®. Summary of product characteristics.
   Google Scholar
• Azilect® summary of product characteristics. Available from: https://www.medicines.org.uk/emc/product/74/smpc. Accessed 531, 2021.
   Google Scholar
• CacciaC, MajR, CalabresiM, et al. Safinamide: from molecular targets to a new anti-parkinson drug. Neurology. 2006;67(7Suppl. 2):S18–S23.44. doi:10.1212/WNL.67.7_suppl_2.S1817030736
   PubMed Web of Science ®Google Scholar
• Mirapexin® 2008. Summary of product characteristics.
   Google Scholar
• Lo MonacoMR, PetraccaM, VetranoDL, et al. Safinamide as an adjunct therapy in older patients with parkinson’s disease: a retrospective study. Aging Clin Exp Res. 2020;32:1369–1373. doi:10.1007/s40520-020-01469-431981101
   PubMed Web of Science ®Google Scholar
• RinaldiD, BianchiniE, SforzaM, et al. The tolerability, safety and efficacy of safinamide in elderly parkinson’s disease patients: a retrospective study. Aging Clin Exp Res. 2020. doi:10.1007/s40520-020-01648-3
   Web of Science ®Google Scholar
• StocchiF, VaccaL, GrassiniP. Overnight switch from rasagiline to safinamide in Parkinson’s disease patients with motor fluctuations: a tolerability and safety study. Eur J Neurol. 2021;28(1):349–354. doi:10.1111/ene.1455232961619
   PubMed Web of Science ®Google Scholar
• SciaccalugaM, MazzocchettiP, BastioliG, et al. Effects of safinamide on the glutamatergic striatal network in experimental parkinson’s disease. Neuropharmacology. 2020;170:108024. doi:10.1016/j.neuropharm.2020.10802432142791
   PubMed Web of Science ®Google Scholar
• GardoniF, MorariM, KulisevskyJ, et al. Safinamide modulates striatal glutamatergic signaling in a rat model of levodopa-induced dyskinesia. J Pharmacol Exp Ther. 2018;367(3):442–451. doi:10.1124/jpet.118.25164530291173
   PubMed Web of Science ®Google Scholar
• FrancescangeliJ, KaramchandaniK, PowellM, BonaviaA. The serotonin syndrome: from molecular mechanisms to clinical practice. Int J Mol Sci. 2019;20(9):2288. doi:10.3390/ijms20092288
   Web of Science ®Google Scholar